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number of scenarios where the EVPI curve takes a different form compared to the 
one illustrated in the typical ‘textbook’ example. For example, when the majority of 
the plotted outcomes are spread over the northern quadrants the traditional EVPI 
peak is absent, and this could be explained by the fact that the reduction in decision 
uncertainty does not outweigh the increased value of opportunity loss. Further, plots 
spread over the eastern quadrants present a maximum EVPI at zero λ which then 
gradually decreases. This study may inform the interpretation of EVPI curves, and 
add value to the analysis of the value of additional research.
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Objectives: Real-world patients do not exhibit the level of medication adherence 
seen in clinical trials. Hence, the effectiveness of medications in routine practice 
may differ. It is important to understand the manifestations of suboptimal medi-
cation adherence in a population to assess the potential of adherence-improving 
interventions and the real-world value of medications. The objective of our study 
was to compare the clinical outcomes of an adherence naïve framework versus 
a dynamic adherence framework using the case of statins for primary preven-
tion of cardiovascular disease versus no statin use. MethOds: Statin adherence 
was categorized as PDC≤ .20, .20< PDC< .80 and PDC≥ .80 based on a longitudinal 
epidemiological cohort study of US medical and pharmacy claims. Yearly adher-
ence transitions were incorporated into a Markov microsimulation using Treeage 
software. Tracker variables were used to store adherence transitions which were 
then used to adjust probabilities of cardiovascular events (MI, stroke, acute angina) 
over the patient’s lifetime. Statin effectiveness was adjusted between 0% and 
100% of trial-based risk reduction. A total of 10,000 microsimulations were used 
to estimate incremental effectiveness as CV events avoided and quality-adjusted 
life-years (QALYs). Results: In the 10,000-patient statin user cohort simulated 
by the adherence-naïve model, it was estimated that statin use resulted in 1,162 
CV events avoided and 0.39 QALYs gained over a lifetime horizon. The dynamic 
adherence model estimated that 42% of patients exhibited highest adherence, 40% 
exhibited intermediate adherence and 18% exhibited low adherence. This model 
simulated that overall, statin use resulted in 366 events were avoided and 0.18 QALYs 
gained. cOnclusiOns: A Markov microsimulation used to simulate changes in 
patients’ medication adherence over time reveals differential risk reduction and 
effectiveness in terms of CV events and QALYs gained. The framework presented 
here is useful for comparing drugs in which optimal effectiveness and costs may 
be similar, but differential adherence may affect outcomes.
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Objectives: In recent years the financer in Hungary (NHIFA) has established a 
detailed and stabile patient turnover database, which reflects time dependent 
changes. Meanwhile, statistical methods of longitudinal data revealing causal 
relationship have been becoming widespread. By these new methods, analyses 
similar to assessment of randomized clinical trials have become available. In 
our research we studied the causal effects of the strategy of treatment, espe-
cially the frequency of retreatment of responder patients on features of status, 
events and costs of patients diagnosed Hepatitis C. MethOds: Causal infer-
ence on longitudinal (e.g. patient path) data is possible using the methods of 
Robins (1999). It makes therapy history exogenous, i.e. independent of the actual 
status of the patient via dynamical, time dependent reweighting of individual 
patient paths. Consequently, patient paths can be analyzed similarly to cohort 
data assessment of randomized clinical trials. The method can be used to con-
firm the results of RCTs. It can substitute RCTs, too, e.g. if RCTs are ethically 
impossible. Results: We obtained by applying Robins’ method that repeated 
combination therapies decreased the risk of liver related complications and the 
development of hepatocellular carcinoma. The method applied to cost analysis 
revealed that despite repeated therapies the costs of newly developed cirrhosis 
and tumor are higher than the corresponding costs of patients with sustained 
viral response. cOnclusiOns: Robins’method is appropriate for measuring the 
causal effects of certain factors of care on patient pathways, especially if patient 
turnover data are supplemented with physiologic, diagnostic and lab information 
found in clinical registers.
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Objectives: Decision analytic modellers use numerous types of evidence for 
populating model parameters. Detailed methodological advice on which type of 
data is to be used for what type of model parameter is required. We aim at review-
ing existing HTA manuals and health economic (modelling) guidelines in order to 
gain advice on appropriate evidence sources for populating models. MethOds: 
We identified manuals and guidelines via the International Network of Agencies 
for Health Technology Assessment (INAHTA) and by hand search. We included 
documents from Europe, the USA, Canada, Australia and New Zealand as well as 
transnational guidelines written in English or German. We systematically sum-
to characterize the underlying disease progression parameters and strengthen 
these assessments.
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Objectives: To identify and compare economic models developed to evaluate the 
cost-effectiveness of treatments for type 2 diabetes mellitus (T2DM), and their use 
in health care decision-making. MethOds: This research updates two previously 
published systematic reviews. The current systematic literature review was per-
formed according to a pre-defined search strategy and review criteria in six com-
monly used databases from September 2008 to January 2013. In addition, websites 
of Health Technology Assessment (HTA) organizations across nine countries and 
major disease conferences’ proceedings were also reviewed. For each identified 
model, key information was extracted and assessed. Results: Overall, 2262 cita-
tions were identified; 122 full text publications, 169 conference proceedings and 106 
HTA reports met the pre-defined inclusion criteria. Among these, 27 models were 
identified; 6 from full text publications, 18 models from conference proceedings, and 
3 models from HTA reports. Most of the included models applied a similar model 
structure, either using Markov-modelling or micro-simulation techniques, and were 
based on similar key data sources. A key challenge of T2DM economic modelling is to 
appropriately predict the long-term progression of relevant risk factors and translate 
these into clinical and economical consequences of diabetes-related complications. 
In line with previous findings, the UKPDS risk equations were most commonly used 
for the above purposes in the newly identified models. Among published studies and 
HTA submissions, T2DM economic models that are widely published and accepted 
by HTAs include CARDIFF and CORE. cOnclusiOns: The most commonly employed 
models in HTA submissions, namely CARDIFF and CORE, have similar techniques 
to forecast future costs and health outcomes. Hence, the focus for decision makers 
should be to consider the appropriateness of the critical assumptions regarding 
data inputs that impact the results.
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Objectives: To estimate the relative efficacy of aclidinium bromide 400 µg 
BID (AB400), to tiotropium bromide 18 µg QD (TIO18) by means of lung function 
in patients with COPD, within the first 24 weeks of treatment and illustrate the 
repeated measures network meta-analysis (NMA) models. MethOds: A system-
atic literature search using a predefined strategy in MEDLINE, EMBASE and the 
Cochrane Library identified 16 unique placebo-controlled RCTs reporting FEV1 
trough: TIO18 (n= 13) and AB400 (n= 3). The development of trough FEV1over time 
for AB400, TIO18 and placebo (PLA) was modeled with fractional polynomials, and 
the difference between the parameters of these polynomials within a trial were 
synthesized across studies with a Bayesian NMA. This type of NMA allows for the 
simultaneous analysis of outcomes at multiple time points. The within-trial cor-
relation was not available from the publications of the included studies, and as 
such a sensitivity analyses was performed assuming different values for the cor-
relation. Results: Given the fractional polynomial parameters obtained with the 
NMA model, the corresponding treatment effects over time for AB400 vs TIO18, 
AB400 vs PLA and TIO vs PLA were estimated. The model with t-0.5and log(t) had 
the best fit according to the deviance information criterion (DIC). These polynomi-
als and within study correlation were used for the modeling of the outcomes over 
time. AB400 is equally efficacious compared to TIO18 during the first 24 weeks, as 
the 95% CrI of the difference in CFB between the treatments includes zero while 
the mean is < 15mL. Furthermore, the probability that each treatment was best was 
calculated as a function of time. cOnclusiOns: This analysis demonstrates the 
use of the proposed NMA models and suggests that maintenance treatment with 
AB400 results in comparable improvements in lung function, as TIO18 in COPD 
patients over a 24 weeks period.
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When making decisions about the allocation of scarce health-care resources it’s 
not only important to consider the estimated cost-effectiveness (CE) with current 
evidence, but also the value of additional research. Expected value of perfect infor-
mation (EVPI) is the amount a decision maker should be willing to pay to eliminate 
uncertainty surrounding the decision about which option is optimal for different 
levels of the CE threshold (λ ). Although EVPI analysis is being requested increasingly 
by reimbursement agencies there is still limited literature on the interpretation 
of EVPI curves. The typical ‘textbook’ example represents just one of the possi-
ble shapes that the curve can take. Objectives: To explore and explain different 
shapes of EVPI curves based on the position of alternative treatment choices on 
the incremental cost-effectiveness plane. MethOds: A hypothetical probabilistic 
decision model was developed in which two interventions were compared. Key 
input parameters were varied to force the model outcomes into different quad-
rants on the incremental CE plane. The population EVPI, based on a hypothetical 
number of future patients and the estimated lifetime of the new intervention, was 
plotted. Results And cOnclusiOns: The result of this study demonstrates a 
